Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Incyte

This Favorable Sign Appears On Incyte's Chart

If history is any guide, there may be good fortune ahead for shares of Incyte (NASDAQ:INCY). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale

The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale

Here's a roundup of top developments in the biotech space over the last 24 hours.

MorphoSys-Incyte Partnered Minjuvi Temporarily Approved In Switzerland

MorphoSys-Incyte Partnered Minjuvi Temporarily Approved In Switzerland

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

FDA Extends Decision Date For Incyte's Ruxolitinib In Vitiligo Skin Disorder

The FDA has extended the review period for Incyte Corporation's (NASDAQ:INCY) supplemental application for ruxolitinib cream (Opzelura) for vitiligo. The Prescription Drug User Fee Act (PDUFA) action date has been extended by three months to July 18 from April 18. The FDA extended the PDUFA action date to review additional data from the ongoing Phase 3…

Why Are Company Insiders Buying These 7 S&P 500 Stocks?

Most investors are likely familiar with the adage, "actions speak louder than words." That saying certainly applies to the executives and other corporate insiders buying and selling shares of their own company's stock.

Insiders Buying Incyte And 2 More Stocks

Although U.S. stock futures traded higher this morning after recording losses on Tuesday, there were a few notable insider trades.

Expert Ratings For Incyte

Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter:

inkl

Read news from The Economist, FT, and more,
with one subscription

Incyte's Return On Capital Employed Insights

Incyte's Return On Capital Employed Insights

According to Benzinga Pro, during Q4, Incyte (NASDAQ:INCY) earned $563.85 million, a 210.25% increase from the preceding quarter. Incyte also posted a total of $862.85 million in sales, a 6.13% increase since Q3.

Why Are Incyte Shares Trading Lower Today?

Why Are Incyte Shares Trading Lower Today?

Incyte Corporation's (NASDAQ: INCY)

Recap: Incyte Q4 Earnings

Recap: Incyte Q4 Earnings

Incyte (NASDAQ:INCY) reported its Q4 earnings results on Tuesday, February 8, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus

Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus

Incyte Corporation (NASDAQ: INCY) is

Where Incyte Stands With Analysts

Where Incyte Stands With Analysts

Within the last quarter, Incyte (NASDAQ:INCY) has observed the following analyst ratings:

1 2 3

Organisations

Bank of America

Incyte Corporation

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Places

418,988 stories

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play